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Background: There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast
cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant
disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which
compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and
treatment arm.
Patients and methods: Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides.
The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan–Meier curves were estimated for
patients with TILs20% and TILs<20%. Median follow-up was 6.1 years.
Results: Median TILs was 5% (Q1–Q3 1%–15%). Increased TILs were independently associated with better DDFS in multivariable model
[hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.59–0.89, P¼ 0.006, for each 10% TILs increment]. Five years DDFS rates were 91.1%
for patients with TILs<20% and 95.7% for patients with TILs20% (P¼ 0.025). The association between 10% TILs increments and DDFS
was significant for patients randomized to 9weeks of trastuzumab (HR 0.60, 95% CI 0.41–0.88) but not for patients treated with 1year of
trastuzumab (HR 0.89, 95% CI 0.71–1.12; test for interaction P¼ 0.088). For patients with TILs<20%, the HR for the comparison between
the short versus the long armwas 1.75 (95% CI 1.09–2.80, P¼0.021); whereas, for patients with TILs20% the HR for the comparison of
short versus long armwas 0.23 (95% CI 0.05–1.09, P¼ 0.064), resulting in a significant interaction (P¼ 0.015).
Conclusions: TILs are an independent prognostic factor for HER2-positive early breast cancer patients treated with adjuvant
chemotherapy and trastuzumab and may refine the ability to identify patients at low risk of relapse eligible for de-escalated
adjuvant therapy.
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Introduction
The standard adjuvant systemic treatment of patients with
HER2-positive early breast cancer includes chemotherapy com-
bined with 1 year of trastuzumab [1].
In this scenario, where many patients experience an excellent
prognosis with standard treatment, one major need is to develop
de-escalated adjuvant treatment strategies for low-risk patients
[2]. Non-inferiority of shorter trastuzumab duration has been
tested in five prospective randomized trials [3–7]: although only
one succeeded in demonstrating the non-inferiority of <1 year
versus 1 year trastuzumab [3], a significant decrease in risk of car-
diac toxicity with shorter treatment clearly emerged [3–7].
Therefore, there is the need for new prognostic and predictive
biomarkers in order to better refine risk classification and identify
HER2-positive patients eligible for de-escalated therapies.
The role of the immune system in breast cancer is being in-
creasingly recognized [8]. Tumor-infiltrating lymphocytes (TILs)
are frequently present in HER2-positive breast cancer [9] and the
mechanism of action of most anti-HER2 therapies implies an
interaction with the immune system [10]. Higher levels of TILs
are associated with increased pathological complete response
rates after neoadjuvant treatment and improved long-term out-
comes for HER2-positive early breast cancer patients [11–16].
However, results of TILs evaluation in the context of two
randomized adjuvant trials of chemotherapy with or without
trastuzumab showed discordant results for TILs prognostic value
according to treatment [14, 16]. No study thus far has explored
the role of TILs in a trial comparing shorter versus 1 year adjuvant
trastuzumab.
In this study we assessed the association between TILs and
long-term outcome for HER2-positive breast cancer patients
enrolled in the randomized phase III ShortHER trial which com-
pared 9weeks versus 1 year of trastuzumab.
Methods
Patients
The ShortHER trial [6] is a phase III multicentric trial of adjuvant ther-
apy that randomized 1253 patients with HER2-positive early breast can-
cer to anthracycline and taxane-based chemotherapy combined with
1 year (arm A, long) or 9weeks (arm B, short) of trastuzumab.
Chemotherapy schedules were also different between the two arms (sup-
plementary material, available at Annals of Oncology online). The study
failed to demonstrate the non-inferiority of 9 weeks of trastuzumab:
5-year disease-free survival rates were 88% in the long and 85% in the
short arm [HR 1.13, 90% confidence interval (CI) 0.89–1.42, pre-defined
non-inferiority margin 1.29] [6].
The present analysis was approved by the competent Ethical
Committee in November 2014, patients provided signed informed con-
sent for tumor sample use for research purpose.
TILs and pathology evaluation
TILs were assessed on a single hematoxylin–eosin stained slide. Stromal
TILs were scored according to pre-defined criteria [17].
All cases were scored by a single investigator (MVD) blinded for clini-
copathological, treatment and follow-up data. A second investigator
(MS) scored 383 cases in order to assess inter-rater agreement. HER-2
and hormone receptors status were assessed locally [6].
Statistical analysis
Statistical analysis was carried out using IBM SPSS Version 24.
Association between variables was evaluated by v2 test or Mann–
Whitney test. Inter-rater agreement was evaluated with weighted j
statistic.
The survival end point was distant disease-free survival (DDFS), calcu-
lated from the time from randomization until distant relapse or death,
whichever first, as defined by DATECAN [18]. The choice of DDFS in-
stead of disease-free survival (which was the primary end point of the
ShortHER trial [6]) was driven by the fact that DDFS includes lethal
events with the strongest impact on overall survival and is considered a
preferred end point to uncover the prognostic value of biomarkers in an-
cillary studies [19].
For survival analysis, TILs were primarily considered as semi-
continuous variable (10% increments). Kaplan–Meier curves were esti-
mated for patients with low and high TILs by adopting the20% cut-off.
The cut-off point was arbitrarily chosen as the one able to identify a
group of patients with a DDFS rate at 5 years of at least 95%, which was
considered a clinically acceptable definition of low-risk patients. The pre-
viously proposed cut-off of TILs50% [14] was not applicable in our
study because too few patients would have been classified as having high
TILs (7.8%, with 1 event only).
Cox proportional regression models were used to calculate hazard
ratio (HR) and 95% CI. Multivariable model included TILs (per 10%
increments), age (continuous), stage (I versus II versus III), hormone re-
ceptor status (positive versus negative) and histologic grade (1–2 versus
3). To study the interaction between treatment arm and TILs, a cox
model including arm, TILs and the interaction term was used. The
Kaplan–Meier method was used to estimate survival curves and the log-
rank test compared between groups. Level of significance was P< 0.05.
No formal sample size calculation was carried out, since the sample
population was based on the number of cases with centralized tumor
samples suitable for the analysis.
Results
Patients characteristics
A total of 866 cases (69% of all randomized patients) were
included in this analysis (TILs cohort, supplementary Figure S1,
available atAnnals of Oncology online). Table 1 shows characteris-
tics of the TILs cohort patients and of patients not included in the
TILs analysis (no-TILs cohort). The majority of TILs cohort
patients were postmenopausal (65%), with stage I or II (85%),
node negative (53%), hormone receptor positive (69%) and
grade 3 tumors (71%). Characteristics were similar in the TILs
cohort and in the no-TILs cohort, with the exception of age: TILs
cohort patients were older than no-TILs cohort patients (median
age 56 versus 54, P¼ 0.014).
The HR for the DDFS comparison between the short versus
long arms was 1.28 (95% CI 0.90–1.81) in all randomized
patients. The HR for DDFS in the TILs cohort was similar (1.37,
95%CI 0.89–2.12).
Tumor-infiltrating lymphocytes
Inter-rater agreement between two investigators, assessed on a
subset of 383 cases, was good for the classification in TILs catego-
ries defined by 10% increments (78% concordance; weighted
Cohen’s j¼ 0.75, 95% CI 0.69–0.81). For further analyses, the
scores of the investigator who reviewed all cases were used.
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Median TILs was 5% (interquartile range 1%–15%). TILs were
significantly higher in younger (<60 years) patients (P¼ 0.018),
and in case of hormone receptor negative (P< 0.001) and Grade
3 tumors (P< 0.001; supplementary Figure S2, available at
Annals of Oncology online). The association between lower TILs
and older age was unlikely confounded by other factors, since the
proportion of hormone receptor positive and grade 1–2 patients
was similar in the two age categories (supplementary Table S1,
available at Annals of Oncology online).
TILs and DDFS
At a median follow-up of 6.1 years, 83 DDFS events occurred.
Increased TILs were associated with better DDFS: the HR for each
10% TILs increment was 0.76 (95%CI 0.62–0.92, P¼ 0.006).
As shown in Figure 1, 5 years DDFS rates were 91.1% for
patients with TILs<20% and 95.7% for patients with TILs20%
(log-rank P¼ 0.025).
In multivariable model (Table 2) TILs 10% increments showed an
independent prognostic value for DDFS (HR 0.73, 95% CI 0.59–0.89,
P¼ 0.002). Stage was the other parameter that was independently
associatedwithDDFS. TILs retained an independent prognostic value
in both hormone receptor positive and negative patients (Table 2).
To further explore the independent prognostic information pro-
vided by TILs and stage, we evaluated the association between TILs
and DDFS in stage-defined subgroups. Results showed a signifi-
cant impact of TILs only for patients with stage II disease (supple-
mentary Figure S3, available atAnnals of Oncology online).
Interaction between TILs and treatment arm
The prognostic value of 10% TILs increments was significant in
the short (HR 0.60, 95% CI 0.41–0.88, P¼ 0.009) but not in the
long arm (HR 0.89, 95% CI 0.71–1.12, P¼ 0.317). The inter-
action test showed P¼ 0.088 (Figure 2A).
A significant interaction between TILs binary variable and
treatment duration was observed (Figure 2B). In the group with
TILs<20%, patients in the long arm experienced a better DDFS
when compared with patients in the short arm: 5 years DDFS
rates were 88.8% for the short and 93.3% for the long arm (HR
short versus long¼1.75, 95% CI 1.09–2.80, P¼ 0.021). To the op-
posite, in the group of patients with TILs20%, the DDFS was
excellent in both arms and numerically superior for patients
treated with short trastuzumab (5 years DDFS 97.6% and 93.7%
Table 1. Baseline characteristics of the patients included (TILs cohort) or not (no-TILs cohort) in the TILs analysis
Characteristics TILs cohort No-TILs cohort All randomized P value
N (%) N (%) N (%)
Randomized 866 (69) 387 (31) 1253 (100)
Age (years) <60 536 (62) 266 (69) 802 (64)
60 330 (38) 121 (31) 451 (36) 0.020
Median (Q1–Q3) 56 (48–64) 54 (46–62) 55 (48–64) 0.014
Menopausal status Premenopausal 300 (38) 148 (38) 448 (36)
Postmenopausal 565 (62) 237 (62) 802 (64) 0.201
AJCC Stage I 155 (40) 509 (41)
II 383 (44) 166 (43) 549 (44)
III 127 (15) 64 (17) 191 (15) 0.681
N stage N0 460 (53) 212 (55) 672 (54)
N1-N2 274 (32) 109 (28) 383 (30)
N3 132 (15) 64 (17) 198 (16) 0.417
Hormone receptors Negative 266 (31) 128 (34) 400 (32)
Positive 600 (69) 251 (66) 853 (68) 0.170
Histological grade
Grade 1- 2 246 (29) 128 (34) 374 (30)
Grade 3 607 (71) 251 (66) 858 (70) 0.082
TILs, tumor-infiltrating lymphocytes; AJCC, American Joint Committee on Cancer.
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Figure 1. Kaplan–Meier curves for distant disease-free survival
according to TILs level.
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for the short and long arm, respectively, HR short versus
long¼0.23, 95% CI 0.05–1.09, P¼ 0.064). Interaction test
showed P¼ 0.015.
Discussion
This is the first study assessing TILs in patients enrolled in a
randomized adjuvant trial comparing shorter versus 1-year tras-
tuzumab. The results, beyond confirming TILs as an independent
prognostic marker for HER2-positive early breast cancer patients,
suggest that higher TILs may discriminate patients at good prog-
nosis who may be optimally treated with shorter trastuzumab. If
further validated in other studies, this may represent the first evi-
dence of potential clinical utility in this setting.
In our study TILs were an independent favorable prognostic
factor for patients treated with adjuvant standard chemotherapy
combined with trastuzumab, both in case of hormone receptor
positive and hormone receptor negative disease. Two previous
studies of adjuvant trastuzumab showed conflicting results: in
Table 2. Multivariate cox models for distant disease-free survival in all patients and in hormone receptor-negative and hormone receptor-positive groups
Factors All patients Hormone receptor negative Hormone receptor positive
HR 95% CI P HR 95% CI P HR 95% CI P
TILs 10% increments 0.73 (0.59–0.89) 0.002 0.73 (0.54–0.98) 0.036 0.73 (0.55–0.98) 0.034
Age (continuous) 1.00 (0.98–1.02) 0.827 1.04 (0.99–1.08) 0.093 0.99 (0.97–1.02) 0.409
AJCC stage III Ref Ref Ref
II 0.41 (0.25–0.67) <0.001 0.30 (0.12–0.72) 0.007 0.47 (0.26–0.85) 0.013
I 0.22 (0.12–0.40) <0.001 0.23 (0.09–0.60) 0.003 0.19 (0.09–0.42) <0.001
Hormone receptors Negative Ref – –
Positive 0.75 (0.47–1.20) 0.231
Grade G3 Ref Ref Ref
G1–2 0.61 (0.36–1.04) 0.069 1.33 (0.52–3.40) 0.551 0.47 (0.24–0.89) 0.021
TILs, tumor-infiltrating lymphocytes; HR, hazard ratio; CI, confidence interval; G, grade.
TILS (10% increments)A
B TIL<20%
Long (Arm A): events 28/345
Short (Arm B): events 45/327
Log-rank P=0.019
HR=1.75, 95% CI 1.09-2.80; P=0.020
Log-rank P=0.044
HR=0.23, 95% CI 0.05-1.09; P=0.064
Long (Arm A): events 8/96
Short (Arm B): events 2/98
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Figure 2. Interaction between TILs and treatment arm. Forest plot shows the prognostic effect on distant disease-free survival of TILs 10%
increments according to trastuzumab duration (A). Kaplan–Meier curves illustrate distant disease-free according to treatment arm (short-
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the FinHER study, a trend for a better DDFS with increased TILs
was reported for patients treated with chemotherapy plus trastu-
zumab [14], whereas in the N9831 trial, a significant association
between high TILs and better recurrence-free survival was
observed only for patients treated with chemotherapy without
trastuzumab [16]. However, another analysis of the N9831 trial
suggested that increased expression of immune-related genes was
associated with improved outcome after trastuzumab treatment
[20]. More recently, Kim et al. [15] reported TILs data from the
NSABP B-31 trial showing an association between increased TILs
and improved outcome that was significant both in the
trastuzumab-treated and trastuzumab-untreated groups.
Overall, these data support the concept that pre-existing im-
mune activation is a determinant of improved outcome for
HER2-positive breast cancer patients treated with chemotherapy
and anti-HER2 therapy. Although general TILs evaluation does
not allow to capture the complexity of the tumor immunemilieu,
it constitutes a simple, inexpensive and reproducible [21] bio-
marker able to discriminate patients at different prognosis inde-
pendently from classic clinicopathological features.
The development of new prognostic biomarkers for HER2-
positive breast cancer patients is of particular relevance in the
actual clinical and research context focused on de-escalated
therapies for low-risk patients.
In our study, the prognostic value of semi-continuous TILs
appeared significant only for patients treated with 9-weeks trastu-
zumab. When comparing the short versus long arm in low and
high-TILs patients, the results suggested that low-TILs patients
benefit from standard 1 year trastuzumab, whereas high-TILs
patients experience an excellent outcome irrespectively of trastu-
zumab duration, with a significant test for interaction. The rate of
events was even lower for patients in the short arm, however the
total number of events was very low. These data indicate that
high TILs may discriminate patients at very good prognosis fol-
lowing treatment with de-escalated trastuzumab duration. These
results need to be further validated. Importantly, decreasing tras-
tuzumab duration is associated with a lower risk of cardiac toxic-
ities [3–6] and this is of particular relevance for real-world
patients, often presenting with higher risk of cardiac events when
compared with patients in clinical trials [22].
The observation that the prognostic value of TILs was mostly
evident for patients with stage II disease is also of potential clinic-
al interest. Indeed, for stage I patients, generally considered at low
risk, effective de-escalated treatments are already available [23],
whereas stage III patients are considered at high risk and deserve
escalated therapies. Stage II patients represent a ‘grey area’ of het-
erogeneous prognosis where a more precise risk stratification is
needed.
We reported in our study median TILs of 5%, which is lower
when compared with other HER2-positive patients cohorts from
adjuvant studies (15% in the FinHER and between 10% and 19%
in the N9831) [14–16, 24]. It is unlikely that this difference is due
tomethodological issues. All these studies applied the same estab-
lished methodology for TILs evaluation [17], which has shown
good reproducibility [21], as also confirmed by our study. One
possible explanationmay be a higher prevalence of older and hor-
mone receptor positive patients in our study. Median age was
56 years in our cohort and 50 years in N9831 [16]; prevalence of
hormone receptor positive patients was 69% in our cohort, 54%
in N9831 [16] and 49% in FinHER [14]. Hormone receptor
positive status is known to be associated with lower TILs [11, 12,
14–16], whereas the correlation between low TILs and older
age observed in our study had not been previously reported.
A hypothesis may be a higher prevalence of luminal intrinsic
subtypes (typically associated with low TILs) in older HER2-
positive/hormone receptor positive patients, as previously sug-
gested [25].
Strengths of this study include: the adoption of a validated
methodology for TILs assessment, the good level of agreement
between two raters, the study design, being the first assessing TILs
in a randomized non-inferiority trial of short adjuvant trastuzu-
mab and the large sample size.
Our study has limitations. First, 69% of cases from the overall
ShortHER population were evaluated for TILs, however this fig-
ure is consistent with other studies [15, 16]. Second, the analysis
was not pre-specified in the protocol. Third, the 20% cut-off
value was arbitrarily chosen, therefore all analyses of TILs as a
binary variable should be considered as exploratory.
In conclusion, TILs are an independent prognostic factor for
patients treated with chemotherapy and adjuvant trastuzumab.
Individual pooled analysis of large studies will be required in
order to draw definitive conclusions on the potential clinical
utility of TILs in selecting patients for de-escalated therapies.
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